Total Payments
$1.6M
2024 Payments
$262,808
Companies
41
Transactions
1,051
Medicare Patients
906
Medicare Billing
$125,627
Payment Breakdown by Category
Other$944,548 (57.5%)
Consulting$521,003 (31.7%)
Travel$133,320 (8.1%)
Research$27,300 (1.7%)
Food & Beverage$16,227 (1.0%)
Education$1,228 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $907,372 | 314 | 55.2% |
| Consulting Fee | $521,003 | 187 | 31.7% |
| Travel and Lodging | $133,320 | 285 | 8.1% |
| Honoraria | $37,176 | 8 | 2.3% |
| Unspecified | $27,300 | 21 | 1.7% |
| Food and Beverage | $16,227 | 231 | 1.0% |
| Education | $1,228 | 5 | 0.1% |
Payments by Type
General
$1.6M
1,030 transactions
Research
$27,300
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $320,742 | 250 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $232,306 | 142 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $217,840 | 95 | $0 (2024) |
| PFIZER INC. | $188,558 | 109 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $97,384 | 82 | $0 (2023) |
| Janssen Biotech, Inc. | $92,407 | 78 | $0 (2024) |
| Takeda Pharmaceutical Company, Limited | $65,920 | 15 | $0 (2018) |
| Lilly USA, LLC | $61,717 | 29 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $33,300 | 19 | $0 (2023) |
| Celltrion USA Inc. | $33,158 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $262,808 | 164 | E.R. Squibb & Sons, L.L.C. ($48,881) |
| 2023 | $264,250 | 165 | E.R. Squibb & Sons, L.L.C. ($95,235) |
| 2022 | $251,379 | 179 | ABBVIE INC. ($115,161) |
| 2021 | $105,997 | 76 | E.R. Squibb & Sons, L.L.C. ($26,440) |
| 2020 | $117,632 | 71 | PFIZER INC. ($18,480) |
| 2019 | $140,830 | 116 | PFIZER INC. ($45,622) |
| 2018 | $334,773 | 156 | Takeda Pharmaceuticals U.S.A., Inc. ($127,130) |
| 2017 | $165,958 | 124 | PFIZER INC. ($49,620) |
All Payment Transactions
1,051 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,445.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $49.65 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $30.21 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Lilly USA, LLC | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Lilly USA, LLC | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 11/08/2024 | Lilly USA, LLC | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 11/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Immunology | ||||||
| 11/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Lilly USA, LLC | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Lilly USA, LLC | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $91.65 | General |
| Category: Immunology | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,577.00 | General |
| Category: Neuroscience | ||||||
| 10/22/2024 | Biocon Biologics Inc | Yesintek (Biological) | Consulting Fee | Cash or cash equivalent | $2,593.35 | General |
| Category: Rheumatology | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Travel and Lodging | Cash or cash equivalent | $160.00 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Food and Beverage | Cash or cash equivalent | $65.00 | General |
| Category: Immunology | ||||||
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $678.28 | General |
| Category: Neuroscience | ||||||
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $308.88 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis | E.R. Squibb & Sons, L.L.C. | $7,000 | 6 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | Eli Lilly and Company | $5,965 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease | E.R. Squibb & Sons, L.L.C. | $5,000 | 4 |
| A Randomized Double Blind Placebo Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate to Severe Crohn s Disease | E.R. Squibb & Sons, L.L.C. | $3,500 | 1 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) | Celgene Corporation | $1,144 | 1 |
| RPC01-202 - PhII UC Touchstone (RPC01-202) (BMS Study Number: IM047-P21) | Celgene Corporation | $1,082 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED OPS-2071 FOR 12 WEEKS IN SUBJECTS WITH CROHNS DISEASE SHOWING SYMPTOMS OF ACTIVE INFLAMMATION DESPITE ONGOING TREATMENT | Otsuka Pharmaceutical Development & Commercialization, Inc. | $825.00 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $655.13 | 1 |
| RPC01-3201 - PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) | Celgene Corporation | $442.00 | 1 |
| RPC01-202 | Celgene Corporation | $417.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 208 | 267 | $140,246 | $30,187 |
| 2022 | 6 | 231 | 295 | $149,835 | $32,106 |
| 2021 | 7 | 241 | 329 | $164,267 | $36,835 |
| 2020 | 8 | 226 | 288 | $138,742 | $26,499 |
Total Patients
906
Total Services
1,179
Medicare Billing
$125,627
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 72 | 108 | $36,180 | $12,190 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 75 | 98 | $23,324 | $7,121 | 30.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 29 | 29 | $37,439 | $4,470 | 11.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 21 | 21 | $26,418 | $3,962 | 15.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 11 | 11 | $16,885 | $2,445 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 96 | 134 | $31,892 | $10,081 | 31.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 60 | 86 | $28,810 | $9,486 | 32.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 35 | 35 | $45,185 | $5,533 | 12.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 16 | 16 | $20,128 | $3,159 | 15.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 12 | 12 | $18,420 | $2,629 | 14.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $5,400 | $1,218 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 98 | 143 | $34,034 | $11,922 | 35.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 49 | 79 | $26,465 | $9,166 | 34.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 35 | 35 | $45,185 | $5,092 | 11.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 18 | 18 | $22,644 | $3,617 | 16.0% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 14 | 14 | $21,490 | $3,150 | 14.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $9,024 | $2,420 | 26.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 25 | $5,425 | $1,468 | 27.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 84 | 110 | $26,180 | $6,324 | 24.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 19 | 19 | $29,165 | $4,418 | 15.1% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 26 | 26 | $33,566 | $3,845 | 11.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 44 | $9,548 | $2,771 | 29.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 26 | 30 | $10,050 | $2,542 | 25.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2020 | 12 | 12 | $15,096 | $2,534 | 16.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 31 | 35 | $8,750 | $2,266 | 25.9% |
About Dr. Stephen Hanauer, MD
Dr. Stephen Hanauer, MD is a Gastroenterology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992868418.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Hanauer, MD has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $262,808 received in 2024. These payments were reported across 1,051 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($907,372).
As a Medicare-enrolled provider, Hanauer has provided services to 906 Medicare beneficiaries, totaling 1,179 services with total Medicare billing of $125,627. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Chicago, IL
- Active Since 12/18/2006
- Last Updated 05/23/2017
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1992868418
Products in Payments
- Entyvio (Biological) $234,624
- ZEPOSIA (Drug) $201,333
- XELJANZ (Drug) $170,294
- SKYRIZI (Biological) $154,224
- STELARA (Biological) $153,080
- ENTYVIO (Biological) $76,698
- RINVOQ (Biological) $62,048
- Humira (Biological) $55,633
- OMVOH (Drug) $45,480
- TREMFYA (Drug) $39,906
- ZYMFENTRA (Biological) $33,158
- HUMIRA (Biological) $20,258
- Non-Covered Product (Drug) $15,497
- SPEVIGO (Drug) $12,900
- INFLECTRA (Biological) $12,294
- RENFLEXIS (Biological) $11,777
- SIMPONI (Biological) $9,004
- IDACIO (Biological) $4,880
- SOTYKTU (Drug) $4,000
- AVSOLA (Biological) $3,924
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Chicago
David Rubin
Gastroenterology — Payments: $1.6M
Gastroenterology $1.6M
Dr. Darren Brenner, M.d, M.D
Gastroenterology — Payments: $1.4M
Gastroenterology $1.4M
Steven Flamm, Md, MD
Gastroenterology — Payments: $1.3M
Gastroenterology $1.3M
Russell Cohen
Gastroenterology — Payments: $834,887
Gastroenterology $834,887
Atman Shah
Gastroenterology — Payments: $766,122
Gastroenterology $766,122
Dr. Parambir Dulai, M.b.b.s, M.B.B.S
Gastroenterology — Payments: $614,180
Gastroenterology $614,180